Stage I findings of a two-stage phase II study to assess the efficacy, safety, and tolerability of barasertib (AZD1152) compared with low-dose cytosine arabinoside (LDAC) in elderly patients (pts) with acute myeloid leukemia (AML).
Giovanni Martinelli
No relevant relationships to disclose
Hagop Kantarjian
Research Funding - AstraZeneca
Elias Jabbour
No relevant relationships to disclose
Alfonso Quintas-Cardama
No relevant relationships to disclose
Kiyoshi Ando
No relevant relationships to disclose
Jacques-Olivier Bay
No relevant relationships to disclose
Andrew Wei
Research Funding - Celgene
Stefanie Gröpper
No relevant relationships to disclose
Kate Owen
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Laura Pike
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Nicola Schmitt
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Paul Stockman
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Aristoteles Giagounidis
No relevant relationships to disclose